They sure make it appear that the CGM market is booming. I'm sure there's a strong future for it, but is it really that strong right now & the near term? Seems like they left out a lot of details, details like real numbers and percentages of users compared to test strips. Instead they say "Many patients are switching to more convenient CGM systems" (context below). "Many" sounds like a lot, but is it really a lot?

Quote:

---

LifeScan became a big player in the blood glucose monitoring market by producing test strip-based devices under the OneTouch brand. Those products remain big sellers for LifeScan but the company faces competition on two fronts. Many patients are switching to more convenient CGM systems. At the same time, rivals with test strip-based devices are creating pricing pressure.

---

They do mention some dollar figures for Abbot and Dexcom, and the numbers seem pretty strong. However, how does this compare to the overall market?

If the CGM market was as strong as this article infers, then why would Platinum consider the purchase of LifeScan a worthy purchase? They paid 2.1 billion for Lifscan. I guess the pie is just really large.

Thanks for the good find, Weave!